ATARA BIOTHERAPEUTICS INC (ATRA)

US0465132068 - Common Stock

12.31  -3.88 (-23.97%)

Premarket: 13.35 +1.04 (+8.45%)

Full estimates are only available for subscribed users, you can see which data is available below.

Subscribed users also see more surprise data, now it is restricted to 4 quarters.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032
Revenue
YoY % growth
20.34M63.57M
212.54%
8.573M
-86.51%
123.44M
1,339.87%
106.39M
-13.81%
72.7M
-31.67%
181.33M
149.42%
126.89M
-30.02%
147.19M
16.00%
209.97M
42.65%
256.99M
22.39%
298.71M
16.23%
EBITDA
YoY % growth
-331.11M
-10.11%
-268.9M
18.79%
-264.447M
1.66%
-67.32M
74.54%
-79.56M
-18.18%
-184.62M
-132.05%
N/A-139.74M-120.36M
13.87%
12.24M
110.17%
88.74M
625.00%
134.64M
51.72%
EBIT
YoY % growth
-340.46M
-10.16%
-274.55M
19.36%
-269.276M
1.92%
-93.541M
65.26%
-106.124M
-13.45%
-146.014M
-37.59%
17.058M
111.68%
-94.35M
-653.11%
-144.84M
-53.51%
-5.1M
96.48%
76.5M
1,600.00%
123.42M
61.33%
Operating Margin
-1,673.84%-431.89%-3,140.98%-75.78%-99.75%-200.84%9.41%-74.36%-98.40%-2.43%29.77%41.32%
EPS
YoY % growth
-90.75
13.78%
-68.00
25.07%
-65.50
3.68%
-8.51
87.00%
-5.45
36.01%
-5.37
1.50%
-2.93
45.44%
-3.83
-30.66%
3.21
184.00%
2.99
-6.98%
N/AN/A

All data in USD

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
Q4 / 24 Q1 / 25 Q2 / 25 Q3 / 25 Q4 / 25
EPS
Q2Q % growth
-2.53
81.91%
0.68
111.89%
-2.18
29.59%
-2.07
29.33%
-3.02
-19.19%
Revenue
Q2Q % growth
27.877M
555.62%
40.8M
49.14%
17.34M
-39.46%
18.87M
-53.05%
14.28M
-48.77%
EBITDA
Q2Q % growth
N/AN/AN/AN/AN/A
EBIT
Q2Q % growth
-18.459M
65.35%
4.59M
117.32%
-17.595M
1.57%
-16.83M
22.65%
-26.01M
-40.91%

All data in USD

Recent Earnings VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q3 2024
Q2Q % growth
-2.93
82.24%
-1.97-0.96-48.64%
Q2 2024
Q2Q % growth
-3.10
81.76%
-1.59-1.51-94.51%
Q1 2024
Q2Q % growth
-5.75
68.06%
-6.540.7912.03%
Q4 2023
Q2Q % growth
-14.00
22.22%
-12.29-1.71-13.90%
Q3 2023
Q2Q % growth
-16.50
19.51%
-16.880.382.26%
Q2 2023
Q2Q % growth
-17.00
-119.35%
-17.150.150.85%
Q1 2023
Q2Q % growth
-18.00
17.24%
-9.99-8.01-80.21%
Q4 2022
Q2Q % growth
-18.00
25.00%
-12.95-5.05-39.04%
Q3 2022
Q2Q % growth
-20.50
8.89%
-20.02-0.48-2.41%
Q2 2022
Q2Q % growth
-7.75
65.93%
-23.6115.8667.18%
Q1 2022
Q2Q % growth
-21.75
-1.16%
-24.993.2412.98%
Q4 2021
Q2Q % growth
-24.00
-1.05%
-17.48-6.52-37.30%
Q3 2021
Q2Q % growth
-22.50
2.17%
-23.901.405.85%
Q2 2021
Q2Q % growth
-22.75
20.18%
-22.74-0.01-0.05%
Q1 2021
Q2Q % growth
-21.50
28.33%
-23.471.978.39%
Q4 2020
Q2Q % growth
-23.75
30.15%
-18.98-4.77-25.13%
Q3 2020
Q2Q % growth
-23.00
29.77%
-27.714.7117.01%
Q2 2020
Q2Q % growth
-28.50
28.75%
-30.161.665.50%
Q1 2020
Q2Q % growth
-30.00
16.67%
-36.076.0716.82%
Q4 2019
Q2Q % growth
-34.00 -34.170.170.50%
Q3 2019
Q2Q % growth
-32.75 -36.764.0110.90%
Q2 2019
Q2Q % growth
-40.00 -38.15-1.85-4.85%
Q1 2019
Q2Q % growth
-36.00 -38.612.616.75%
Recent Revenue VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q3 2024
Q2Q % growth
40.19M
1,779.79%
35.871M4.319M12.04%
Q2 2024
Q2Q % growth
28.64M
2,892.69%
40.79M-12.15M-29.79%
Q1 2024
Q2Q % growth
27.357M
2,131.40%
25.184M2.173M8.63%
Q4 2023
Q2Q % growth
4.252M
1,832.73%
11.783M-7.531M-63.91%
Q3 2023
Q2Q % growth
2.138M
-52.06%
4.853M-2.715M-55.94%
Q2 2023
Q2Q % growth
957K
-98.14%
3.843M-2.886M-75.10%
Q1 2023
Q2Q % growth
1.226M
-83.23%
31.291M-30.065M-96.08%
Q4 2022
Q2Q % growth
220K
-97.09%
40.466M-40.246M-99.46%
Q3 2022
Q2Q % growth
4.46M
-16.95%
5.381M-921K-17.12%
Q2 2022
Q2Q % growth
51.58M
1,232.82%
6.974M44.606M639.60%
Q1 2022
Q2Q % growth
7.31M
105.92%
5.011M2.299M45.88%
Q4 2021
Q2Q % growth
7.55M 35.846M-28.296M-78.94%
Q3 2021
Q2Q % growth
5.37M 4M1.37M34.25%
Q2 2021
Q2Q % growth
3.87M 3.918M-48K-1.23%
Q1 2021
Q2Q % growth
3.55M 1.629M1.921M117.93%
Q4 2020
Q2Q % growth
13.6M-13.6M-100.00%
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPS0% -1577.93% 0% -10.75%
Revenue0% 7.8% -1.97% 11.55%